ONESOURCE
Invest with MTF
Invest Now
Invest in OneSource Specialty Pharma with 3.1X leverage
Performance
- Low
- ₹1,700
- High
- ₹1,749
- 52 Week Low
- ₹1,210
- 52 Week High
- ₹2,248
- Open Price₹1,709
- Previous Close₹1,723
- Volume60,685
Investment Returns
- Over 1 Month + 8.18%
- Over 3 Month -0.22%
- Over 6 Month -12.93%
- Over 1 Year + 4.25%
Smart Investing Starts Here Start SIP with OneSource Specialty Pharma for Steady Growth!
OneSource Specialty Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 499.3
- PEG Ratio
- 4.2
- Market Cap Cr
- 19,949
- P/B Ratio
- 3.4
- Average True Range
- 61.13
- EPS
- 12.04
- Dividend Yield
- 0
- MACD Signal
- -18.88
- RSI
- 56.03
- MFI
- 66.82
OneSource Specialty Pharma Financials
OneSource Specialty Pharma Technicals
EMA & SMA
Current Price
₹1,741.00
+
18
(1.04%)
- Bearish Moving Average 4
- Bullish Moving Average 12
- 20 Day
- ₹1,674.34
- 50 Day
- ₹1,714.01
- 100 Day
- ₹1,750.88
- 200 Day
- ₹1,732.20
Resistance and Support
1710.9
- R3 1,792.10
- R2 1,761.00
- R1 1,742.00
- S1 1,691.90
- S2 1,660.80
- S3 1,641.80
OneSource Specialty Pharma Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-11 | Quarterly Results | |
| 2025-08-04 | Quarterly Results | |
| 2025-05-05 | Audited Results | |
| 2025-01-29 | Quarterly Results |
OneSource Specialty Pharma F&O
About OneSource Specialty Pharma
- NSE Symbol
- ONESOURCE
- BSE Symbol
- 544292
- Managing Director & CEO
- Mr. Neeraj Sharma
- ISIN
- INE013P01021
Similar Stocks to OneSource Specialty Pharma
OneSource Specialty Pharma FAQs
OneSource Specialty Pharma share price is ₹1,741 As on 26 December, 2025 | 15:59
The Market Cap of OneSource Specialty Pharma is ₹19949.3 Cr As on 26 December, 2025 | 15:59
The P/E ratio of OneSource Specialty Pharma is 499.3 As on 26 December, 2025 | 15:59
The PB ratio of OneSource Specialty Pharma is 3.4 As on 26 December, 2025 | 15:59
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.